Intratumoral administration of lipid nanoparticles that express mRNA for the cytokines IL-23 and IL-36γ, along with the T-cell costimulator OX40L, have led to in situ vaccination and CD8+ T-cell dependent tumor regression in both colon cancer and melanoma models. This evidence concerns the gene CD8A and melanoma.